AstraZeneca Bolsters Immunology Footprint with US$39 B Alexion Buyout
By Michelle Liu;
Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)
Published: 16 Dec-2020
DOI: 10.3833/pdr.v2020.i12.2579 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to bolster its immunology and rare disease pipeline, AstraZeneca (AZ) has agreed to purchase Alexion Pharmaceuticals for a total consideration of US$39 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS